Teva to Host Conference Call and Webcast on November 30, 2012

  Teva to Host Conference Call and Webcast on November 30, 2012

Business Wire

JERUSALEM -- November 29, 2012

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will
host a conference call and live webcast on Friday, November 30, 2012 at 8:00
a.m. ET to communicate its 2013 business outlook. A Question & Answer session
will follow.

A live webcast of the call will be available on Teva's website at: Please log in at least 10 minutes prior to the
conference call in order to download the applicable audio software. The call
can also be accessed by calling (at least 10 minutes before the scheduled
start time) 1-888-771-4371 (U.S.) and 1-847-585-4405 (International). The
conference ID or passcode is 33802130.

Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company's website. The replay can also be
accessed until December 7, 2012, at 11:59 p.m. ET by calling 1-888-843-7419
(U.S.) or 1-630-652-3042 (International). The conference ID or passcode is

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as specialty pharmaceuticals and active pharmaceutical ingredients.
Headquartered in Israel, Teva is a world leading generic drug maker, with a
global product portfolio of more than 1,300 molecules and a direct presence in
about 60 countries. Teva's branded businesses focus on CNS, oncology, pain,
respiratory and women's health therapeutic areas. Teva currently employs
approximately 46,000 people around the world and reached $18.3 billion in net
revenues in 2011.

Teva’s Safe Harbor Statement under the U.S. Private Securities Litigation
Reform Act of 1995:

The following discussion and analysis contains forward-looking statements,
which express the current beliefs and expectations of management. Such
statements involve a number of known and unknown risks and uncertainties that
could cause our future results, performance or achievements to differ
significantly from the results, performance or achievements expressed or
implied by such forward-looking statements. Important factors that could cause
or contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products, competition from
the introduction of competing generic equivalents and due to increased
governmental pricing pressures, the effects of competition on sales of our
innovative medicines, especially Copaxone® (including competition from
innovative orally-administered alternatives as well as from potential generic
equivalents), potential liability for sales of generic medicines prior to a
final resolution of outstanding patent litigation, including that relating to
our generic version of Protonix®, the extent to which we may obtain U.S.
market exclusivity for certain of our new generic medicines, the extent to
which any manufacturing or quality control problems damage our reputation for
high quality production and require costly remediation, our ability to
identify, consummate and successfully integrate acquisitions (including the
acquisition of Cephalon), our ability to achieve expected results through our
innovative R&D efforts, dependence on the effectiveness of our patents and
other protections for innovative medicines, intense competition in our
specialty pharmaceutical businesses, uncertainties surrounding the legislative
and regulatory pathway for the registration and approval of
biotechnology-based medicines, our potential exposure to product liability
claims to the extent not covered by insurance, any failures to comply with the
complex Medicare and Medicaid reporting and payment obligations, our exposure
to currency fluctuations and restrictions as well as credit risks, the effects
of reforms in healthcare regulation and pharmaceutical pricing and
reimbursement, adverse effects of political instability and adverse economic
conditions, major hostilities or acts of terrorism on our significant
worldwide operations, increased government scrutiny in both the U.S. and
Europe of our agreements with brand companies, interruptions in our supply
chain or problems with our information technology systems that adversely
affect our complex manufacturing processes, the impact of continuing
consolidation of our distributors and customers, the difficulty of complying
with U.S. Food and Drug Administration, European Medicines Agency and other
regulatory authority requirements, potentially significant impairments of
intangible assets and goodwill, potential increases in tax liabilities
resulting from challenges to our intercompany arrangements, the termination or
expiration of governmental programs or tax benefits, any failure to retain key
personnel or to attract additional executive and managerial talent,
environmental risks, and other factors that are discussed in our Annual Report
on Form 20-F for the year ended December 31, 2011 and in our other filings
with the U.S. Securities and Exchange Commission (“SEC”). Forward-looking
statements speak only as of the date on which they are made, and we undertake
no obligation to update any forward-looking statements or other information
contained in this report, whether as a result of new information, future
events or otherwise.


Teva Pharmaceutical Industries Ltd.
Kevin C. Mannix
United States
Joseph Marczely
United States
Tomer Amitai
972 (3) 926-7656
Hadar Vismunski-Weinberg
972 (3) 926-7687
Denise Bradley
United States
Press spacebar to pause and continue. Press esc to stop.